The global biotechnology and life sciences industry is preparing for one of its most significant annual gatherings as the BIO International Convention 2026 is set to take place from June 22-25, 2026, at the San Diego Convention Center in California, USA. Organised by the Biotechnology Innovation Organization (BIO), the event will bring together biotechnology leaders, pharmaceutical companies, investors, researchers, policymakers, startups, and healthcare innovators from across the world.
Recognised as one of the world’s leading biotechnology collaboration platforms, BIO 2026 is expected to attract more than 20,000 participants and over 1,600 exhibitors representing more than 70 countries. The convention will serve as a major hub for networking, investment discussions, scientific exchange, and strategic partnerships across the biotech ecosystem.
Spanning four days, the convention will feature more than 130 conference sessions covering 18 focus areas, including AI and digital health, cell and gene therapy, oncology, diagnostics, personalized medicine, biomanufacturing, vaccines, rare diseases, translational research, intellectual property, regulatory innovation, and global market opportunities. Industry experts, business leaders, and policymakers will discuss the future of healthcare innovation, biotechnology commercialization, and next-generation therapeutics.
The event will also showcase BIO Partnering™, the organisation’s proprietary meeting platform designed to facilitate business matchmaking and strategic collaborations among biotech companies, investors, pharmaceutical firms, and research institutions. In 2025, the convention recorded more than 66,000 partnering meetings, highlighting its role as a major catalyst for global biotech deal-making and innovation partnerships.
In addition to the exhibition and conference programs, BIO 2026 will host networking sessions, company presentations, investor meetings, country pavilions, and innovation showcases designed to accelerate collaboration across the life sciences value chain. The event is expected to further strengthen San Diego’s position as a leading global destination for biotechnology, healthcare innovation, and international business events.
